EurekAlert!

PBPK model precisely predicts drug–drug interactions between prodrug GP681 and CYP3A4 inhibitors, offering new guidance for safe influenza therapy

A physiologically based pharmacokinetic (PBPK) model developed for suraxavir marboxil (GP681) and its active metabolite ...
Science Daily

Study provides scaffold to selectively target drug breakdown process

Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
Seeking Alpha

U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
Seeking Alpha

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...